Reolysin: Completed Phase II enrollment

Oncolytics completed enrollment in the open-label, U.S. Phase II REO 017 trial evaluating first-line therapy with gemcitabine plus IV Reolysin every 3 weeks in 33 patients. Last year, Oncolytics repor...